GSE146982 metformin 0 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE146982_metformin_0_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE146982_metformin_0_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE146982_metformin_0_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE146982_metformin_0_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

mitochondrial ribosomal protein S18B

Gene

long intergenic non-protein coding RNA 511

Gene

PSMG3 antisense RNA 1

Gene

cytokine receptor like factor 2

Gene

MIR31 host gene

Gene

uncharacterized LOC101928188

Gene

PDCD6-AHRR readthrough (NMD candidate)

Gene

ribosomal protein L7a pseudogene 76

Gene

long intergenic non-protein coding RNA 242

Gene

eukaryotic translation initiation factor 4A1 pseudogene 10

  • Gene

    mitochondrial ribosomal protein S18B


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    PSMG3 antisense RNA 1


  • Gene

    cytokine receptor like factor 2



  • Gene

    uncharacterized LOC101928188


  • Gene

    PDCD6-AHRR readthrough (NMD candidate)


  • Gene

    ribosomal protein L7a pseudogene 76


  • Gene

    long intergenic non-protein coding RNA 242


  • Gene

    eukaryotic translation initiation factor 4A1 pseudogene 10

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.